Is EGFR-targeted therapy safe with heart failure?

Question

Hello doctor,

I am a 62-year-old male recently diagnosed with stage III non-small cell lung cancer. My oncologist recommended comprehensive cancer genome testing, and the results showed an EGFR exon 19 deletion.

I was advised to start targeted therapy with Osimertinib, but I also have chronic heart failure with a reduced ejection fraction of 30 percent, for which I am on Carvedilol, Furosemide, and Spironolactone.

My NT-proBNP is elevated at 3200 pg/mL, and I still get fatigued even with mild exertion.

I am concerned about how this targeted therapy might affect my heart, especially since I have already had two hospitalizations in the past year due to fluid overload and shortness of breath.
Are EGFR inhibitors safe for someone with heart failure?
Could they worsen my cardiac function or cause arrhythmias?
Is there any alternative treatment that would be gentler on the heart?
Also, how often should I be monitored for cardiac side effects during cancer treatment?
I want to proceed with therapy, but I am worried about trading one life-threatening condition for another. How do we balance both?

Please help.

Thank you.

Answer 1

Hello,

Welcome to icliniq.com.

I have read your query and can understand your concern.

So In your situation, starting Osimertinib for EGFR-mutated (estimated glomerular filtration rate mutated, a specific gene mutation exists in cancer cells) NSCLC (non-small cell lung cancer, it occurs when abnormal cells form and multiply in your lungs) requires careful coordination with your cardiologist, because while EGFR inhibitors (estimated glomerular filtration rate inhibitors) are generally considered less cardiotoxic than some chemotherapy or other targeted agents, they can rarely cause heart rhythm disturbances, QT prolongation (a heart electrical disturbance, visualized on an ECG (electrocardiogram) as an abnormally long time for the ventricles to recharge between beats), or fluid retention, which could exacerbate your pre-existing heart failure.

Given your reduced ejection fraction, elevated NT-proBNP (N-terminal pro-B-type natriuretic peptide, a blood test marker that indicates increased pressure and stress on the heart, primarily used to diagnose or rule out congestive heart failure), and history of hospitalizations for fluid overload, close cardiac monitoring is essential. This typically includes baseline and periodic ECGs (electrocardiograms), echocardiograms to track ejection fraction, and regular assessment of symptoms, weight, and electrolytes. Dose adjustments or temporary pauses may be needed if cardiac issues arise.

Alternatives with potentially lower cardiac risk are limited, but sequential chemotherapy with careful fluid management or enrollment in clinical trials with newer targeted therapies may be considered.

The key is a multidisciplinary approach. Your oncologist and cardiologist should collaborate to weigh the benefits of treating the lung cancer against the risks to your heart, optimize heart failure medications, monitor closely for early warning signs, and adjust therapy promptly. With careful planning, it is possible to treat the cancer effectively while minimizing additional cardiac risk.

I hope this answers your query.

Please let me know if I can assist you further.

Thank you.